« Previous Next » Seizure: European Journal of Epilepsy
Volume 19, Issue 4 , Pages 226-231 , May 2010

GABA_B receptor activation exacerbates spontaneous spike-and-wave discharges in DBA/2J mice

Marco Bortolato
- Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, USA
- Department of Neurological and Cardiovascular Sciences, University of Cagliari, Italy
- Corresponding authors at: Department of Neurological and Cardiovascular Sciences, University of Cagliari, Policlinico Universitario, S.S. 554 Km 4.500, 09042 Monserrato (CA), Italy. Tel.: +39 070 51096191; fax: +39 070 51096032.
Roberto Frau
- Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, USA
- Department of Neuroscience Bernard B. Brodie, University of Cagliari, Italy
Marco Orrù
- Department of Neuroscience Bernard B. Brodie, University of Cagliari, Italy
Mauro Fà
- Department of Neuroscience Bernard B. Brodie, University of Cagliari, Italy
Christian Dessì
- Department of Neuroscience Bernard B. Brodie, University of Cagliari, Italy
Monica Puligheddu
- Department of Neurological and Cardiovascular Sciences, University of Cagliari, Italy
Luigi Barberini
- Department of Neurological and Cardiovascular Sciences, University of Cagliari, Italy
Giuliano Pillolla
- Department of Neuroscience Bernard B. Brodie, University of Cagliari, Italy
Lorenzo Polizzi
- Department of Neurological and Cardiovascular Sciences, University of Cagliari, Italy
Federico Santoni
- Department of Neurological and Cardiovascular Sciences, University of Cagliari, Italy
Giampaolo Mereu
- Department of Experimental Biology and CNR Neuropsychopharmacology Section, University of Cagliari, Italy
Francesco Marrosu
- Department of Neurological and Cardiovascular Sciences, University of Cagliari, Italy
- Corresponding authors at: Department of Neurological and Cardiovascular Sciences, University of Cagliari, Policlinico Universitario, S.S. 554 Km 4.500, 09042 Monserrato (CA), Italy. Tel.: +39 070 51096191; fax: +39 070 51096032.

Received 18 July 2009 ,Revised 13 February 2010 ,Accepted 19 February 2010.

Baclofen increases number and mean duration of spike-and-wave discharges (SWDs), but does not affect their morphology. EEG patterns before (a) and after (b) baclofen treatment (5mg/kg, i.p.). (c) Numb

Baclofen increases number and mean duration of spike-and-wave discharges (SWDs), but does not affect their morphology. EEG patterns before (a) and after (b) baclofen treatment (5mg/kg, i.p.). (c) Number and (d) mean duration of SWDs after different baclofen doses (0.5–10mg/kg, i.p.). Values are expressed as mean SWDs±S.E.M. White columns: baseline SWDs; black columns: SWDs after baclofen injection; Baclofen doses are indicated in mg/kg (i.p.). VEH, vehicle. *p<0.05, **p<0.01, in comparison to relative baseline. n=5–7 for each group. For further details, see text.
- Full-Size Image
- Download to PowerPoint
Baclofen reduces locomotor activity of DBA/2J mice in a dose-dependent fashion. Values are expressed as mean±S.E.M. Baclofen doses are indicated in mg/kg (i.p.). VEH, vehicle. *p<0.05 in comparison

Baclofen reduces locomotor activity of DBA/2J mice in a dose-dependent fashion. Values are expressed as mean±S.E.M. Baclofen doses are indicated in mg/kg (i.p.). VEH, vehicle. *p<0.05 in comparison to VEH-treated mice in the same time point. n=5 for each group. For further details, see text.
- Full-Size Image
- Download to PowerPoint
GBL modifies the number, mean duration and morphology of spike-and-wave discharges (SWDs). EEG patterns before (a) and after (b) GBL treatment (100mg/kg, i.p.). (c) Number and (d) mean duration of SWD

GBL modifies the number, mean duration and morphology of spike-and-wave discharges (SWDs). EEG patterns before (a) and after (b) GBL treatment (100mg/kg, i.p.). (c) Number and (d) mean duration of SWDs after different GBL doses (5–100mg/kg, i.p.). Values are expressed as mean SWDs±S.E.M. White columns: baseline SWDs; black columns: SWDs after GBL injection; GBL doses are indicated in mg/kg (i.p.). VEH, vehicle. *p<0.05, **p<0.01, in comparison to relative baseline. n=5–7 for each group. For further details, see text.
- Full-Size Image
- Download to PowerPoint
GBL reduces locomotor activity of DBA/2J mice in a dose-dependent fashion. Values are expressed as mean±S.E.M. Baclofen doses are indicated in mg/kg (i.p.). VEH, vehicle. *p<0.05 in comparison to V

GBL reduces locomotor activity of DBA/2J mice in a dose-dependent fashion. Values are expressed as mean±S.E.M. Baclofen doses are indicated in mg/kg (i.p.). VEH, vehicle. *p<0.05 in comparison to VEH-treated mice in the same time point. n=5 for each group. For further details, see text.
- Full-Size Image
- Download to PowerPoint
SCH50911 reverses both baclofen (BAC)- and GBL-induced SWD modifications in DBA/2J mice. (a) Number and (b) mean duration of SWDs after SCH50911 (50mg/kg, i.p.) in combination with BAC (5mg/kg, i.p.),

SCH50911 reverses both baclofen (BAC)- and GBL-induced SWD modifications in DBA/2J mice. (a) Number and (b) mean duration of SWDs after SCH50911 (50mg/kg, i.p.) in combination with BAC (5mg/kg, i.p.), GBL (100mg/kg, i.p.) or their vehicle (VEH). Values are expressed as mean SWDs±S.E.M. White columns: baseline SWDs; black columns: SWDs after treatment. **p<0.01, in comparison to relative baseline; ^##p<0.01 in comparison to VEH-treated animals. n=8–10 for each group. For further details, see text.
- Full-Size Image
- Download to PowerPoint